AegirBio

In line with this decision, AegirBio will continue to offer its current MagniaReader and the two TDM tests for the MagniaReader, albeit exclusively for research purposes and will thus not uphold the CE markings for the said PoC tests for infliximab (Remicade) and natalizumab (Tysabri). These resources will be dedicated to bolstering the core focus areas of the company.

Marco Witteveen, CEO of AegirBio, expressed enthusiasm about this strategic pivot, stating, "This decision enables us to channel our energies towards delivering a sophisticated platform that aligns with the evolving needs and expectations of both physicians and patients. It empowers us to forge a path towards cutting-edge healthcare solutions."

AegirBio is poised to leverage this shift in strategy to spearhead the development of a state-of-the-art platform, positioning itself at the forefront of the healthcare industry. This pivotal move underscores the company's commitment to advancing healthcare accessibility and patient-centric solutions.